Scleroderma (SSc) is a fibrosing connective tissue disease that is poorly responsive to any treatment, including immune suppression. SSc shares many characteristics with chronic graft-versus-host disease (GVHD). Because the immunomodulatory drug thalidomide has proven beneficial in chronic GVHD, we studied the immune response and clinical effects of thalidomide in SSc patients. We treated 11 SSc patients with thalidomide in an open label, dose escalating, 12 week study. Histologic comparison of skin biopsies showed changes in skin fibrosis and an increase in epidermal and dermal infiltrating CD8 ؉ T cells with thalidomide treatment. In thalidomide-treated SSc patients, plasma levels of IL-12 and TNF-␣ increased, while plasma IL-5 and IL-10 levels remained unchanged. These changes were associated with clinical effects, including dry skin, dermal edema, transient rashes, decreased gastroesophageal reflux symptoms, and healing of digital ulcers. When SSc PBMCs activated by anti-CD3 mAb were exposed to thalidomide, increases in both production of IL-2, IL-3, GM-CSF, and IFN-␥ and T cell expression of CD40L were observed. Thalidomide therefore appears to induce immune stimulation in SSc patients in association with clinical changes. However, it remains to be shown whether long-term enhancement of immune responses in SSc patients is clinically beneficial.
INTRODUCTION
Progressive systemic sclerosis (scleroderma; SSc) is a connective tissue disorder of unknown etiology which affects about 36,000 persons in the United States (reviewed in 1, 2). The disease is characterized by fibrosis of skin, resulting in progressive restriction of joint range of motion. Fibrosis of internal organs also occurs, leading to cardiac dysrhythmias, gastroesophageal reflux, and respiratory problems. The vasculature is affected by the fibrotic process, resulting in ischemia due to narrowing of the arterial lumen. Recurrent digital ulcers are also characteristic of the disease. The progressive fibrosis causes marked disability and increased mortality. Because it is believed to be an autoimmune disease, SSc is often treated with immunosuppressive and cytotoxic drugs, none of which have been shown to modify the disease course.
Recently, investigators have begun to characterize the immune parameters of this disease. Results suggest that a T helper 2 (Th2)-type immune response predominates (3) (4) (5) . The affected skin of SSc patients has been shown to contain mRNA for interleukin-4 (IL-4), but not for interferon-gamma (IFN-␥). CD4
ϩ T cell clones generated from SSc skin biopsies have been shown to express this Th2-type cytokine profile (6) . Also, defective IFN-␥ production by in vitro stimulated peripheral blood cells from SSc patients has been reported and abnormally low IFN-␥ levels have been observed in SSc sera (3) . During the early inflammatory stage of SSc, activated T cells infiltrate the perivascular and interstitial spaces of the skin (7, 8) . This infiltrating cell population contains both CD4 ϩ and CD8
ϩ T cells, with a predominance of CD4 ϩ cells. Systemic T cell and monocyte activation are indicated by the elevated serum levels of soluble IL-2 receptor (sIL-2R), soluble intercellular adhesion molecule-1 (sI-CAM-1), tumor necrosis factor-alpha (TNF-␣), IL-2, IL-4, IL-6, and IL-10 (3, 4, 9 -11).
SSc shares many characteristics with chronic graftversus-host disease (GVHD), including fibrosis of skin and visceral organs with involvement of the salivary glands, gastrointestinal tract, liver, and lung (12) (13) (14) . Chronic GVHD is also associated with a Th2 immune response (15) . In patients with chronic GVHD refractory to conventional therapy, thalidomide treatment has resulted in clinical improvement (16) . In animal models of both acute and chronic GVHD, a progressive reduction of cutaneous fibrosis and a return of normal dermal appendages has been observed with thalidomide treatment, with further and possibly synergistic efficacy seen in combination therapy with cyclosporin A (CSA) (17, 18) .
Investigators in this laboratory have previously shown that thalidomide is a partial inhibitor of TNF-␣ production by LPS-stimulated monocytes both in vitro and in vivo (19, 20) . More recently, we have shown that thalidomide is also a potent costimulator of human T cells in vitro (21) . Addition of a specific T cell stimulus (anti-CD3 mAb) to peripheral blood cells in vitro in the presence of thalidomide results in increased production of IFN-␥, IL-2, and IL-12 as well as enhanced T cell expression of CD40 ligand (CD40L) (22) . Thus, thalidomide appears to stimulate a Th1-type cellular immune response.
We hypothesized that thalidomide, an effective immune-modulating treatment in chronic GVHD, might similarly modify the immune status of SSc patients, thereby altering scleroderma disease activity. To test this hypothesis we carried out a pilot study in which 8/11 SSc patients completed a 3-month course of thalidomide treatment. Immunologic status, clinical symptoms, and skin biopsy histology were evaluated. Because of the possibility of disease exacerbation by a shift toward a Th1-type immune response in SSc patients, we chose a relatively short treatment protocol with dose escalation.
MATERIALS AND METHODS
Study patients. Four male and 7 female subjects, aged 18 to 70, who met the American College of Rheumatology criteria (23) for either diffuse (9/11) or limited (2/11) scleroderma were enrolled into the study over a 3-year period. Enrolled subjects were not on any immunomodulating treatment other than a stable dose of 5 mg/day prednisone (patients 1, 2, 7) in the 4 weeks prior to the protocol. Patients were allowed to remain at a stable corticosteroid dose and no additional immunomodulating agents were introduced during the protocol. Patient 8, who had been taking both prednisone and CSA for the previous year, was allowed to remain on stable doses of prednisone (20 mg/day) and of CSA (150 mg/day) during thalidomide treatment. Patient exclusion criteria included systemic sclerosing-like illnesses associated with known environmental, ingested, or injected agents or with other connective tissue diseases. This study was conducted according to established ACR guidelines for clinical trials in scleroderma (24) . Patients gave informed consent for the study protocol, which had been approved by the Rockefeller University Institutional Review Board.
All patients studied were required to practice effective contraception for at least 1 month prior to study entry and to use at least two forms of contraception for the duration of the study and for 60 days post completion of the study. All women of child bearing potential were required to have a negative pregnancy test (serum ␤-HCG) at the time of screening and at each clinical evaluation time point of the protocol.
Protocol. All patient evaluations took place in the inpatient and outpatient facilities of The Rockefeller University Hospital and were performed by the same physician throughout the protocol. Subjects meeting entry criteria were admitted to the Hospital for a 36-h visit at week 0 for measurement of baseline study parameters. Initial dosing of thalidomide (generously provided by Celgene, Warren, NJ) was 50 mg/day orally. Repeat study parameter evaluations were performed during inpatient visits at weeks 2, 4, 8, and 12. At each visit the thalidomide dose was doubled. The final thalidomide dose, administered between weeks 8 and 12, was 400 mg/day. This is the maximum dose used to treat erythema nodosum leprosum in leprosy patients (25) .
Blood collection. EDTA anticoagulated blood samples were collected from 8 of the 11 study patients at baseline (week 0) and protocol time points (weeks 2, 4, 8, and 12). Within 30 min of phlebotomy, the plasma was removed by centrifugation at 4°C and stored at Ϫ70°C until analysis. Similarly, blood samples were obtained from 21 normal, healthy laboratory personnel (11 males, 10 females), with a median age of 35 years and a range of 23 to 70 years. In addition, at least 1 year after completion of the study, blood samples for in vitro studies were obtained from patients 2, 5, 6, and 7 at a time when they had not been on any immunemodulating treatment, including thalidomide, during the previous year. Blood for in vitro studies was also collected from 4 additional patients with diffuse SSc: 3 females, ages 47, 57, and 59, and 1 male, aged 68, who were not on any immune-modulating therapies.
Cytokine determination. Cytokine and soluble surface protein levels were determined according to manufacturer's instructions using commercial ELISA kits. The following kits were utilized: TNF-␣ EASIA, IL-3, IL-4, IL-5 (Biosource International, Camarillo, CA), IFN-␥, GM-CSF, sIL-2R, IL-10, IL-12, and sICAM-1 (Endogen, Woburn, MA). Samples were assayed in duplicate and compared to a standard curve, using a microtiter plate reader (Dynatech, Chantilly, VA).
Histology and immunohistology. Four-to six-millimeter punch biopsy samples from disease-affected areas were obtained at week 0 from four patients (5, 6, 9, 10). After 12 weeks of thalidomide treatment, a second biopsy was obtained from a site immediately adjacent to the first biopsy site. Tissue samples were fixed in 10% buffered Formalin, embedded in paraffin, and then sectioned and stained with H&E for microscopic viewing. Sections for immunostaining were pretreated with Antigen Unmasking Solution (Vector Laboratories, Burlingame, CA) and then incubated with a primary mouse anti-human mAb against CD8 (Dako Corp., Carpinteria, CA) at 1:25. Control sections were incubated with whole mouse IgG (Jackson Immunoresearch Laboratories, Inc., West Grove, PA). The sec-tions were then incubated with a secondary goat antimouse mAb conjugated with Texas Red at 1:300 (Jackson Lab., PA). Tissue samples from patients 9 and 10 were divided in two at the time of biopsy, with half processed as above and the other half embedded in OCT and frozen. The frozen sections were later fixed in acetone for 10 min. Prepared sections were stained with chromophore-labeled mAbs (FITC-CD4, RPE-CD8) or isotype controls (IgG1-FITC, IgG1-RPE) (Dako, CA). Specimens were examined using an Olympus epifluorescence microscope, equipped with a CCD camera (Hamamatsu) and Metamorph deconvolution software (Universal Imaging, West Chester, PA).
Counting of CD8
ϩ cells was done directly from the sections using the 40X objective. (21). PBMCs were isolated from blood of scleroderma patients by Ficoll-Hypaque density gradient centrifugation. The recovered leukocytes were washed three times with cold PBS prior to plating in triplicate in RPMI 1640 media (GIBCO, Grand Island, NY) supplemented with 10% AB ϩ human serum, 2 mM L-glutamine, 100 units/ml penicillin, and 100 g/ml streptomycin (GIBCO) in anti-CD3-coated 48-well plates. A stock solution of thalidomide was prepared by dissolving the drug in DMSO at a stock concentration of 20 mg/ml. Cultures were treated daily with the appropriate dilutions of thalidomide or DMSO. At the indicated times, supernatants were harvested and frozen immediately at Ϫ70°C until assay by ELISA as described above. Cells were harvested at 48 h and analyzed with chromophore-labeled mAb (CD4-FITC, CD8-FITC, CD154-PE, and CD3-APC) on a FACStar three-color cytometer (Becton-Dickinson, San Jose, CA).
Statistical analysis. This study, with a small sample size, was designed as a feasibility study. Individual patient data are graphically presented along with median group values unless otherwise indicated. Nonparametric comparisons of clinical and laboratory data were performed using SPSS software (version 7.0, SPSS Inc., Chicago, IL) employing the Wilcoxon signed ranks test and Mann-Whitney test for paired and independent samples, respectively.
RESULTS
Response to thalidomide and effects on clinical symptoms. Eleven patients were enrolled into the study over a 3-year period (Table 1) . Nine patients had diffuse disease and 2 patients had limited disease at the time of enrollment. The median age was 42 years, with females comprising 64% of the study group. Ten patients had detectable antinuclear antibodies, 4 had antibodies to topoisomerase-1 (SCL 70), and 1 had anticentromere antibodies. The median disease duration was 1 year (range 0.5-4 years).
Eight patients completed the 3-month treatment protocol. Three patients dropped out of the protocol within 1 month of enrollment: two patients (Nos. 4 and 7) for non-drug-related reasons and one patient (No 1) for an apparent allergic reaction to thalidomide that consisted of abdominal cramping, skin rash, and markedly increased levels of circulating and dermal infiltrating eosinophils.
Two specific side effects of thalidomide, pruritus and dry skin, were noted in seven of the eight patients by 4 weeks into the study. Nonpitting extremity edema was seen in seven patients during the protocol period. This may have contributed to our finding that skin scores (26) remained unchanged during the 12-week treatment period. Macular, erythematous rashes occurred in two patients; one of these had a persistent rash during weeks 8 -12 and the second patient experienced a diffuse rash at week 2, with complete spontaneous resolution within 48 h. One patient noted transient morning paresthesias in his extremities throughout his treatment. Symptoms of dysphagia, constipation, and sedation due to thalidomide were minimal and well tolerated.
Consistent changes in absolute peripheral blood leukocyte counts were noted in patients receiving thalidomide (Table 2) . A reduction in the overall leukocyte count due to decreased neutrophils was observed in all patients while on thalidomide. Eosinophil and basophil counts increased in all patients, with peak median counts observed at week 8. Numbers of lymphocytes and monocytes were unaffected.
Gastroesophageal reflux (GER), as defined by the b Subepidermis is defined as an area starting at the dermal/epidermal border and extending into the dermis approximately 400 m (1 high-powered field diameter).
FIG. 2.
The effect of thalidomide on the histopathology of the skin. The histology of skin biopsies obtained from three SSc patients are shown (A, B, patient 6; C, D, patient 10; E-H, patient 9) before thalidomide treatment (left column) and after 12 weeks of treatment (right column). A and C show a thickened epidermis and scattered mononuclear cells infiltrating the superficial dermis (40X). B and D show a more compact epidermis after 12 weeks of thalidomide treatment (40X). E shows atrophy of skin appendages in the dermis and dense collagen fibers (10X). Note the presence of mononuclear inflammatory infiltrates around vessels and within collagen fibers. G shows dense collagen fibers and scattered cell nuclei (40X). F shows decreased skin fibrosis with thinner collagen fibers (10X) after 12 weeks of thalidomide therapy. In H, note the thinner collagen fibers and increased cellularity (40X objective). 113 subjective presence of nocturnal and postprandial heartburn symptoms, improved progressively and resolved by week 12 in 6/8 patients. No changes or additions were made in previously established anti-reflux treatments in patients while participating in the study.
Five patients had chronic extremity ulcers prior to treatment. Digital ulcers resolved completely in 4/5 patients by week 12 (Fig. 1) . There was no relationship between ulcer healing in these patients and seasonal temperature variations. Two patients experienced a 
T cells at study entry (A, B) and after 12 weeks of thalidomide treatment (C, D). Few CD8
ϩ cells are present in the lower epidermis, upper dermis, and perivascular regions prior to treatment. After thalidomide treatment, a marked increase in the number of infiltrating CD8 ϩ cells is apparent. E and F contain comparable views of a consecutive section from C and D, stained as negative controls. Cell nuclei are counterstained with Hoechst blue (see Table 3 for quantification).
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OLIVER, MOREIRA, AND KAPLAN return of their digital ulcers within a year of discontinuing thalidomide. A third patient remained continuously on thalidomide and did not experience further ulcer formation during 1 year of treatment. A fourth patient had not experienced further digital ulcers at 4 months after having stopped treatment with thalidomide. In a fifth patient, who had been on a stable dose of CSA during the previous year, complete healing of a chronic malleolus ulcer was seen at week 2 of thalidomide treatment. This patient, who was able to continue his occupation as a manual laborer, experienced new extremity ulcers while on thalidomide that ultimately responded to antibiotic therapy initiated after completion of the study.
Patient 10 was allowed to continue treatment under our supervision after having completed the 12-week protocol period. After 1 year of thalidomide treatment, he had experienced changes, including regrowth of hair and softening of the skin on his forearms, suggesting clinical improvement. However, we cannot rule out that these clinical changes occurred as a natural consequence of his disease course.
Changes in skin fibrosis and skin adnexia. To determine the effect of thalidomide treatment on the fibrotic skin of SSc patients, punch biopsies of involved skin at adjacent locations were obtained from four patients at weeks 0 and 12 of the protocol. Histologic sections of pretreatment skin showed the typical findings of scleroderma, including a marked increase in the deposition of compact collagen in the dermis associated with atrophy of skin appendages (Fig. 2) . Mononuclear inflammatory cell infiltration around blood vessels in the collagen was noted. Skin biopsies obtained after 12 weeks of thalidomide treatment in these individuals consistently showed loosening of the collagen fibers in the dermis and decreased thickness of the epidermal layer.
Changes in CD4
ϩ and CD8 ϩ T cells in the skin. Thalidomide has previously been shown to increase the number of CD8 ϩ T cells in the circulation of HIV ϩ individuals (27) . Immunohistologic staining of both paraffin-embedded and frozen (data not shown) tissue biopsy samples obtained from SSc patients revealed consistent increases in the numbers of CD8 ϩ lymphocytes in the skin after 12 weeks of thalidomide treatment compared to pretreatment biopsies ( Table 3 ). The CD8 ϩ lymphocytes were predominantly located in (Fig. 3) . No obvious change in the numbers of CD4 ϩ cells in the dermis was noted following treatment with thalidomide.
Changes in plasma cytokines and soluble ligands.
Thalidomide treatment also affected plasma cytokine levels. At baseline, plasma levels of TNF-␣, IL-12, sIL-2R, and sICAM-1 were elevated in SSc patients compared to normal control subjects (Table 4) . During treatment with thalidomide, further increases over baseline values were observed in plasma levels of TNF-␣ and IL-12 (Fig. 4) . The increases in median TNF-␣ plasma levels peaked at week 4, followed by a return to pretreatment levels. Progressive increases in ϩ T lymphocytes staining for CD4 or CD8 are also shown. Data are presented for each individual evaluated (E) and the median of the group ( ). Statistically significant differences between thalidomide-treated and untreated (0 g/ml) cells are denoted as follows: *P 0.0117, a P 0.0499.
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OLIVER, MOREIRA, AND KAPLAN median plasma IL-12 levels peaked at week 8. Plasma levels of IL-5 and IL-10 were low at baseline in SSc patients and were comparable to levels found in the normal control group. No changes in the levels of plasma IL-10 or sIL-2R occurred during thalidomide treatment, while sICAM-1 levels exhibited a slight downward trend with treatment (data not shown). Neither IL-4 nor IFN-␥ was detectable in plasma from normal controls or from SSc patients.
In vitro responses of PBMCs. To determine whether thalidomide exerted a direct immunostimulatory effect on SSc T cells, PBMCs were obtained from SSc patients who were not receiving thalidomide. When PBMCs from these untreated individuals were activated in vitro with anti-CD3 mAb, IL-2, IL-4, IL-5, and IFN-␥ were detectable in the supernatants (Fig. 5) . The addition of thalidomide to these cultures did not affect the levels of IL-4 detected in supernatants. However, IL-2 and IFN-␥ levels were significantly enhanced in a dosedependent manner in response to thalidomide. CD40 ligand (CD40L; CD154), expressed on activated T cells, is a costimulatory molecule that is a critical component in many aspects of the immune response, including T-cell-dependent activation of antigen-presenting cells (APCs) and the subsequent production of IL-12 by the APCs. We therefore examined the in vitro effect of thalidomide on T cell expression of CD40L (Fig. 5 ). When T cells purified from the peripheral blood of SSc patients were stimulated with anti-CD3 mAb in the presence of thalidomide, we observed a significant increase in the surface expression of CD40L on CD4 ϩ and CD8 ϩ T cells. Similar increases in cytokine production and CD40L expression were seen in thalidomidetreated PBMCs obtained from normal volunteers (data not shown).
Changes in hematopoietic factors. To address the observed increases in circulating eosinophils and basophils in these patients during thalidomide treatment, we also measured hematopoietic factors associated with these leukocyte subsets. When PBMCs were activated by immobilized anti-CD3 mAbs, dose-dependent increases were observed in supernatant levels of both GM-CSF and IL-3 (Fig. 6) , while a decrease occurred in IL-5 levels (Fig. 5) . IL-5 plasma levels in SSc patients did not show any appreciable change in response to thalidomide treatment (data not shown). Neither IL-3 nor GM-CSF was detectable by ELISA in plasma from patients or normal volunteers.
DISCUSSION
The lack of any effective treatment for the progressive autoimmune disease SSc underscores the importance of understanding the disease pathogenesis and identifying new therapeutic interventions. Our observations, although preliminary and derived from a small group of patients, suggest that immune activation with the drug thalidomide may provide a new treatment option. However, a larger, placebo-controlled study of longer duration will be necessary to determine whether the drug has clinical efficacy in SSc. With the exception of one patient who had an apparent allergic reaction to the drug, thalidomide was well tolerated in this group without evidence of SSc disease exacerbation. 
THALIDOMIDE IMMUNOMODULATION IN SCLERODERMA
A striking clinical effect observed in these patients was the healing of digital and other extremity ulcers while being treated with thalidomide. Surprisingly, signs and symptoms of digital vasospasm in these patients did not change during the 3-month course of treatment, suggesting that improved cutaneous blood circulation was not responsible for these clinical benefits. However, improved ulcer healing by thalidomide in other disease processes, including pyoderma gangrenosum (28 -30) and aphthous ulcers (31, 32) , suggests that healing of SSc digital ulcers may not be dependent on changes in blood circulation. Recently, thalidomide was shown to increase both proliferation and migration of keratinocytes in vitro (33) , which may contribute to its effects on ulcer healing. In addition, the thalidomide-associated increases in GM-CSF observed in vitro (Fig. 6) in PBMCs of SSc patients provide a possible mechanism for the enhanced ulcer healing observed. Our laboratory has previously shown that GM-CSF stimulates keratinocyte proliferation both in vitro and in vivo and enhances wound healing in lepromatous leprosy patients (34 -36) . More recently, topical GM-CSF has been reported effective in healing chronic venous ulcers (37) as well as the healing of aphthous ulcers in HIV ϩ patients (38) . The thalidomide-induced increase in PBMC production of GM-CSF also provides a possible explanation for the thalidomide-associated increases in peripheral circulating eosinophils; a leukocyte subset whose specific growth factors include GM-CSF. The relationship between thalidomide and GM-CSF will be explored in further studies.
The immune stimulatory effect of thalidomide observed in this study is noteworthy. In these patients, we observed that thalidomide induces an increase in plasma IL-12 and TNF-␣ levels. The observation of immune stimulation in vivo was confirmed by experiments in vitro, in which SSc PBMCs exposed to thalidomide and anti-CD3 mAb showed upregulation of CD40L expression and release of increased amounts of the Th1-type cytokines IL-2 and IFN-␥.
IL-12 is an important immunoregulatory cytokine produced by APCs , including macrophages, dendritic cells, and B cells (reviewed in 39). IL-12 production by macrophages can be triggered both directly via LPS stimulation and indirectly by activated T cells through ligation of CD40 (40) . This cytokine is a powerful inducer of IFN-␥ production by T and NK cells, leading to the development of Th1-type immune responses important for protection against intracellular pathogens, such as mycobacteria and viruses. IL-12 has also been implicated in animal models of autoimmune disease. In a murine model, administration of IL-12 has been shown to inhibit acute GVHD and delay mortality of chronic GVHD (41) . Unexpected benefits from IL-12 treatment were also observed in a rat model of T-cellmediated uveitis (42) . Taken together, these observations suggest that in the SSc patients on thalidomide, increased IL-12 production may have contributed to the clinical effects noted.
Our present results suggest that skin differentiation, including collagen biosynthesis and the organization of dermal adnexia, may be affected by systemic immune activation and cytokine production. Indeed, it has been shown that cytokine production following selective activation of either Th1 or Th2 T cell subsets can exert opposing effects on collagen synthesis by dermal fibroblasts. IL-4, produced by Th2-type lymphocytes, is an activator of collagen production (43) . Also, anti-IL-4 treatment in the "tight skin" mouse model of scleroderma has been shown to prevent dermal collagen deposition (44) . In contrast, IFN-␥ is a potent inhibitor of collagen biosynthesis (45, 46) and has been shown to completely suppress IL-4-induced collagen gene expression by both normal and SSc dermal fibroblasts (47) . In SSc patients, a selective deficiency in IFN-␥ production has been observed in cultured dermal (6) and blood (3) lymphocytes. Clinical trials using IFN-␥ treatment in SSc patients have shown mild beneficial effects on skin sclerosis parameters (48, 49) . In the present study, the thalidomideinduced increases in IL-12 levels may up-regulate IFN-␥ production by T cells in the skin, as suggested by in vitro studies, potentially leading to a reduction in collagen biosynthesis. This possibility will be examined in future studies.
In previous studies, we had focused on the ability of thalidomide to inhibit TNF-␣ production in vivo and in vitro (19, 20) . More recently, we found that thalidomide affects TNF-␣ in a differential manner. The drug inhibits TNF-␣ production by monocytes but does not inhibit TNF-␣ production by T cells (19, 21, 22) . It is possible that the TNF-␣ observed in the plasma of these patients is produced by T cells and therefore not blocked by thalidomide. Alternatively, T cell activation during thalidomide treatment may have stimulated increased TNF-␣ production. We have also investigated the effect of the drug on IL-12 production. Thalidomide was shown to inhibit IL-12 production by monocytes stimulated in vitro by LPS (a T-cell-independent stimulus), but to increase IL-12 production by monocytes in vitro in the presence of T cells activated via the T cell receptor (22) . Furthermore, these effects by thalidomide on T cells could be blocked by antibodies to IL-2 but not by antibodies to IL-4. The present observation that thalidomide induces an increase in IL-12 and TNF-␣ in vivo suggests that the drug may be preferentially affecting T cell activation and T-celldependent cytokine production in SSc patients. This is the first study in which the clinical and immune effects of thalidomide have been reported in SSc patients. However, these clinical results are primarily descriptive and are derived from a small group of pa-118 tients treated for a short period of time. The in vivo and in vitro results suggest that immune stimulation by thalidomide may be a potential therapeutic intervention in SSc. Longer term, placebo-controlled studies will be necessary to show whether thalidomide-induced immune changes can lead to sustained beneficial clinical effects in SSc patients and others with related autoimmune disorders.
